BridgeMD
New treatment option for Myofascial Pain Dysfunction Syndrome
Official title Magnesium Sulfate as an Adjuvant to Lidocaine in MPDS Trigger Point Injections Assessed by VAS and sEMG.
ClinicalTrials.gov ID: NCT07390851
What this study is testing
What is Lidocaine 2% (preservative-free, without vasoconstrictor)?
Lidocaine 2% (preservative-free, without vasoconstrictor) is an investigational medicine, given as an injection into a muscle, being studied as a potential treatment for myofascial pain dysfunction syndrome.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Age between 18 and 70 years.
- Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
- Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
- Pain duration ≥ 3 months.
- Pain intensity ≥ 4 on the Visual Analog Scale (VAS).
You likely can't join if
- Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.
- Current use of anticoagulants or history of bleeding disorders.
- Systemic or local infection at or near the injection site.
- History of fibromyalgia, central pain syndromes, or cancer-related pain.
- Major psychiatric illnesses (e.g., schizophrenia, severe depression).
- Recent surgery or trauma to the head, neck, or upper back (\<6 months).
See the full eligibility criteria
- Age between 18 and 70 years.
- Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
- Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
- Pain duration ≥ 3 months.
- Pain intensity ≥ 4 on the Visual Analog Scale (VAS).
- Noprior trigger point injection in the affected area within the past 3 months.
- Ability and willingness to provide informed consent.
- Compliance with study visits and procedures
- Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.
- Current use of anticoagulants or history of bleeding disorders.
- Systemic or local infection at or near the injection site.
- History of fibromyalgia, central pain syndromes, or cancer-related pain.
- Major psychiatric illnesses (e.g., schizophrenia, severe depression).
- Recent surgery or trauma to the head, neck, or upper back (\<6 months).
- Use of analgesics (NSAIDs, opioids) within 5 days before intervention.
- Severe systemic diseases:- Uncontrolled diabetes mellitus- Liver or kidney failure- Severe cardiovascular conditions.
The study team makes the final eligibility decision.
Where it's taking place
- Giza, Giza Governorate, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Giza, Giza Governorate, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.